Risk factors
BioRestorative Therapies (BRTX) risk factors
Item 1A of every BioRestorative Therapies, Inc. 10-K on file, and what changed from one year to the next.
- FY2025 10-K risk factors
55 risks, 5 new, 1 dropped, 6 reworded since the prior year. Company faces Nasdaq delisting threat after shares dropped to $0.33, and key executive employment agreements expired in March 2026 without extension.
Filed Mar 26, 2026 - FY2024 10-K risk factors
51 risks. The company relies heavily on ongoing financing to fund its pre-revenue cell therapy development, particularly for product candidate BRTX-100.
Filed Mar 28, 2025